Trump’s Executive Order on Drug Prices Faces Criticism Over Foreign Interests
In a move that garnered significant praise, President Donald Trump announced an executive order on Monday aimed at lowering prescription drug prices in the U.S. The initiative encourages drug manufacturers to voluntarily reduce prices, with the federal health department compensating them for the lowered rates through programs like Medicare and Medicaid.
During the announcement, Trump stated, “We’re going to be equal… we’re going to pay what Europe pays.” This sentiment was echoed by conservative commentator Peter Schweiser, who highlighted the disparity in pricing for medications like the asthma inhaler Qvar, which costs $289 in the U.S. yet only $9 in Germany. Schweiser suggests that Trump’s emphasis on reducing prices underlines his commitment to ordinary Americans, who often face much higher drug costs.
However, alongside this announcement, Trump faced scrutiny over plans to retrofitting a Boeing 747 previously owned by the Qatari royal family for use by the Air Force. Critics from both sides of the political spectrum have deemed this move a potential violation of the constitutional emoluments clause, raising questions about Trump’s susceptibility to foreign interests.
Schweiser supports the prescription drug initiative as a rational strategy, arguing it addresses the underlying pricing issues without merely imposing caps. He likens the current pharmaceutical landscape to NATO, where the U.S. bears much of the cost while other countries benefit from lower prices.
While the Biden administration received praise for similar efforts aimed at negotiating drug prices, Schweiser notes that Trump’s executive orders are broader in scope. Co-host Eric Eggers pointed out that a lack of congressional action has allowed large corporations to continue influencing policy through lobbying and advertising, particularly around drug prices.
Furthermore, the plane deal has been labeled by some as a political gift that could give Democrats an advantage. Trump’s intent to accept a $400 million jet from Qatar presents a legal gray area, approved by Attorney General Pam Bondi, who has ties to lobbying efforts for the Qatari government. Schweiser contends this raises ethical concerns, especially when compared to the scrutiny faced by Hunter Biden regarding his foreign business dealings.
Schweiser cautions that the implications of accepting such a gift are troubling, especially given Qatar’s history of sponsoring terrorism. The security risks associated with the aircraft are notable too; he referenced previous concerns regarding Chinese tech companies potentially embedding espionage tools in government equipment.
Commentators have speculated that Trump’s actions may serve to provoke Boeing, suggesting the negotiation might actually be closer to a $4 billion contract than to the military’s actual needs. Given the complexities involved with retrofitting a Boeing 747, doubts linger about the feasibility of such a plan.
In conclusion, Schweiser highlights an inconsistency in the criticism leveled at Trump’s foreign dealings, questioning why similar concerns about Qatari investments in American universities seem to be overlooked by his opposing faction.
